The recognition and patent application of R&D achievements by stages are also based on rigorous scientific research achievements. Ad5-nCoV vaccine not only achieved good immunogenicity in animal experiments, but also achieved good results in clinical trials of 1-2.
Security can be guaranteed. The results showed that the proportion of adverse reactions such as fever, fatigue and pain at the injection site in the vaccinated subjects was significantly higher than that in the placebo group. However, most of the adverse reactions are mild or moderate, and the most common third-grade adverse reaction is fever.
Extended data:
Matters needing attention
In order to promote the research and development and production of vaccines in COVID-19, this requirement refers to the laws, regulations and standards related to biosafety at home and abroad, closely combines the requirements of good manufacturing practice, and puts forward biosafety requirements based on the biosafety risks in the whole process of vaccine production.
1, dividing the protection level of vaccine production workshop.
2. It is stipulated that workshops and facilities, production equipment, verification and evaluation should be carried out in accordance with the relevant requirements of low and high biosafety risks.
3. Put forward clear requirements and measures for biosafety.
People's Network-Promoting Vaccine R&D and Biosafety of Vaccine Production Workshop issued by COVID-19 Production Department 5.